The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide - Schmitt, Stefan; Ho, Anthony Dick; Goldschmidt, Hartmut (Onkologie, 2010)
Gesehen am 14.06.2023